Clinical trial
Exploratory Next Generation Sequencing to Identify Causative Variants for Therapy-Induced Congestive Heart Failure From Breast Cancer Study E5103 Germline DNA Samples
NCT02610426 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Exploratory Next Generation Sequencing to Identify Causative Variants for Therapy-Induced Congestive Heart Failure From Breast Cancer Study E5103 Germline DNA Samples
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- March 25, 2014
- Completion date
- January 1, 2100
- Enrollment
- 162 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
breast carcinoma